Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	KIT V654A
Gene Variant Detail	KIT V654A (unknown)
Relevant Treatment Approaches

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 19 of 19 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
KIT exon13	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 5% (1/19) and partial response in 21% (4/19) of melanoma patients harboring KIT exon 11 or exon 13 mutations (PMID: 28843487; NCT01168050).	28843487
KIT exon13	melanoma	predicted - sensitive	Imatinib	Phase II	Actionable	In a Phase II trial, Gleevec (imatinib) treatment resulted in a 6-month progression-free survival (PFS) rate of 36.6%, a median PFS of 3.5 months, a median overall survival (OS) of 14.0 mo, a 1-year OS rate of 51.0%, partial responses (PR) in 23.3% (10/43) and stable disease in 30.2% of metastatic melanoma patients harboring KIT mutations, 9 of the 10 responders harbored KIT exon 11/ 13 mutations (PMID: 21690468; NCT00881049).	21690468
KIT mutant	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) treatment in patients with melanoma harboring KIT mutations resulted in an overall response rate of 26.2% (11/42), which included 11 patients with a partial response, a median duration of response of 7.1 months, and an overall survival of 18 months (PMID: 28327988; NCT01028222).	28327988
KIT mutant	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 4% (1/25), durable partial response in 16% (4/25), and stable disease in 56% (14/25) of melanoma patients harboring KIT mutations (PMID: 28843487; NCT01168050).	28843487
KIT mutant	mucosal melanoma	predicted - sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial (NICAM), Tasigna (nilotinib) treatment demonstrated activity in patients with acral (n=6) or mucosal melanoma (n=20) harboring KIT mutations, resulting in a progression-free survival at 6 months in 25% (6/24) of the patients, a median-progression free survival of 3.7 months, objective response rate at 12 weeks of 19% (5/26), and median overall survival of 7.7 months (PMID: 38417447).	38417447
KIT mutant	acral lentiginous melanoma	predicted - sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial (NICAM), Tasigna (nilotinib) treatment demonstrated activity in patients with acral (n=6) or mucosal melanoma (n=20) harboring KIT mutations, resulting in a progression-free survival at 6 months in 25% (6/24) of the patients, a median-progression free survival of 3.7 months, objective response rate at 12 weeks of 19% (5/26), and median overall survival of 7.7 months (PMID: 38417447).	38417447
KIT mutant	gastrointestinal stromal tumor	predicted - sensitive	Ripretinib	Phase I	Actionable	In a Phase I trial, Qinlock (ripretinib) demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including KIT-mutant gastrointestinal stromal tumor (GIST), with 1 patient harboring KIT exon 11 and 17 mutations demonstrating a partial response, and 7/7 KIT-mutant GIST patients demonstrating a partial metabolic response (EORTC-NCI-AACR 2016, Abs 7LBA).	detail...
KIT mutant	gastrointestinal stromal tumor	predicted - sensitive	Avapritinib	Phase I	Actionable	In a Phase I (NAVIGATOR) trial, Ayvakit (avapritinib) treatment resulted in an objective response rate of 13% (7/52, 7 partial responses) and a disease control rate of 63% (33/52) in patients with KIT-mutant gastrointestinal stromal tumor (The CTOS 2018 Annual Meeting, Nov 14-17, Rome Italy, Paper 012 3027631; NCT02508532).	detail...
KIT mutant	gastrointestinal stromal tumor	predicted - sensitive	Ripretinib	Phase I	Actionable	In a Phase I trial, Qinlock (ripretinib) was well tolerated, resulted in an objective response in 11.3% (16/142, 16 partial responses) and stable disease in 61.3% (87/142) of patients with advanced gastrointestinal stromal tumor harboring KIT (exon 11, n=103; exon 9, n=26; other, n=6) or PDGFRA mutations (n=7), with a median progression-free survival of 5.6 months (PMID: 32804590; NCT02571036).	32804590
KIT mutant	melanoma	predicted - sensitive	Ripretinib	Phase I	Actionable	In a Phase I trial, Qinlock (ripretinib) treatment demonstrated manageable safety and preliminary efficacy in patients with KIT-mutated melanoma, and led to an objective response rate of 23% (6/26, 1 complete and 5 partial responses), a median progression-free survival of 7.3 months, and a median duration of response of 9.1 months (PMID: 35753087; NCT02571036).	35753087
KIT exon13	melanoma	not predictive	Pembrolizumab	Clinical Study	Actionable	In a retrospective analysis, real-world treatment with either Keytruda (pembrolizumab) or Toripalimab (JS001) resulted in a median disease-free survival of 33 months in melanoma patients harboring KIT mutations in either exon 11 (64.8%), exon 13 (17.6%), or exon 17 (17.6%) compared to 32 months in patients with wild-type BRAF, NRAS, and KIT (p=0.200) (PMID: 37403699).	37403699
KIT exon13	melanoma	not predictive	Toripalimab-tpzi	Clinical Study	Actionable	In a retrospective analysis, real-world treatment with either Keytruda (pembrolizumab) or Loqtorz (toripalimab-tpzi) resulted in a median disease-free survival of 33 months in melanoma patients harboring KIT mutations in either exon 11 (64.8%), exon 13 (17.6%), or exon 17 (17.6%) compared to 32 months in patients with wild-type BRAF, NRAS, and KIT (p=0.200) (PMID: 37403699).	37403699
KIT mutant	gastrointestinal stromal tumor	not applicable	N/A	Clinical Study	Diagnostic	KIT mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 25193432, PMID: 26276366, PMID: 25729899).	25193432 26276366 25729899
KIT exon13	melanoma	sensitive	Nilotinib	Case Reports/Case Series	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), which included a partial response in 7.7% (1/13) of melanoma patients harboring KIT exon 13 mutations (PMID: 28327988).	28327988
KIT exon13	melanoma	sensitive	Regorafenib	Case Reports/Case Series	Actionable	In a Phase II trial, second or later-line Stivarga (regorafenib) treatment resulted in a disease control rate of 73.9% (17/23, 2 complete responses, 5 partial responses), an objective response rate of 30.4% (7/23), and median overall survival (mOS) of 21.5 months in patients with melanoma harboring KIT exon 9, 11, 13, or 17 mutations, and improved mOS in patients with non-exon 11 mutations compared to patients with exon 11 mutations (24.9 mo vs 18.3 mo, P=0.042) (PMID: 37741071; NCT02501551).	37741071
KIT exon13	melanoma	predicted - sensitive	Imatinib	Case Reports/Case Series	Actionable	In a Phase II trial, Gleevec (imatinib) treatment resulted in a best overall response rate of 53.8% (7/13, all partial responses), a disease control rate of 76.9% (10/13), a median time-to-progression of 3.9 months, and a median overall survival of 12.9 months in patients with mucosal, acral, or chronically sun-damaged skin melanoma harboring KIT activating mutations in exons 11 (n=9), 13 (n=3), and 17 (n=1) (PMID: 23775962; NCT00424515).	23775962
KIT mutant	gastrointestinal stromal tumor	sensitive	Imatinib + Infigratinib	Preclinical - Pdx	Actionable	In a preclinical study, Truseltiq (infigratinib) and Gleevec (imatinib) combination treatment demonstrated enhanced antitumor activity in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT mutations (PMID: 25673643).	25673643
KIT exon13	gastrointestinal stromal tumor	sensitive	Imatinib + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a gastrointestinal stromal tumor cell line harboring a KIT exon 13 mutation in culture (PMID: 27370604).	27370604
KIT exon13	gastrointestinal stromal tumor	sensitive	Adavosertib + Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Adavosertib (MK-1775) and Ayvakit (avapritinib) synergized to inhibit growth of a gastrointestinal stromal tumor cell line harboring a KIT exon 13 mutation in culture (PMID: 33320833).	33320833

Showing 1 to 19 of 19 entries

Filter rows: